imatinib mesylate has been researched along with Calcification, Pathologic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Artiach, G; Bäck, M; Carracedo, M; Ehrenborg, E; Eriksson, P; Franco-Cereceda, A; Pawelzik, SC; Pieterman, E; Plunde, O; Pouwer, MG; Princen, HMG; Saliba-Gustafsson, P; Stenke, L | 1 |
| Eslamy, HK; Quon, A | 1 |
2 other study(ies) available for imatinib mesylate and Calcification, Pathologic
| Article | Year |
|---|---|
The tyrosine kinase inhibitor nilotinib targets the discoidin domain receptor DDR2 in calcific aortic valve stenosis.
Topics: Animals; Aortic Valve; Aortic Valve Stenosis; Calcinosis; Cells, Cultured; Discoidin Domain Receptor 2; Discoidin Domain Receptors; Humans; Imatinib Mesylate; Mice; Protein Kinase Inhibitors; Pyrimidines | 2022 |
PET/CT imaging of gastrointestinal stromal tumor with calcified peritoneal implants after imatinib therapy.
Topics: Antineoplastic Agents; Benzamides; Calcinosis; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Peritoneum; Piperazines; Positron-Emission Tomography; Prostheses and Implants; Pyrimidines; Tomography, X-Ray Computed | 2008 |